• Warnings for Drug-Drug Interactions in Consumer Medication Information Provided by Community Pharmacies

      Malone, Daniel; Panich, Jennifer; Gooden, Andrea; College of Pharmacy, The University of Arizona (The University of Arizona., 2018)
      Objective: In 2006, the Food and Drug Administration (FDA) outlined standards for consumer medication information (CMI) that pharmacies should provide to patients receiving new prescription medications. The objective of this study was to evaluate the CMI provided by six pharmacy chains for accuracy and completeness with respect to drug-drug interactions (DDIs). Methods: Medication leaflets were obtained from six different community pharmacy chains located in southern Arizona. Three medications chosen: azithromycin, ciprofloxacin, and simvastatin. The content of the information in the leaflets was examined and compared to information two drug information sources. The number of and information for DDIs mentioned in the CMI was evaluated. The reading level of each CMI was evaluated using the Flesch-Kincaid reading level scale. Results: The CMI provided by the six pharmacies appear to be produced by two information vendors, Wolter’s Kluwer or First Databank. This was evident based on the identical wording and reference to these sources. The CMI from First Databank mentioned 5 of the 11 known interactions with the target medications. The CMI that was developed by Wolter’s Kluwer mentioned only 2 of the 11 known DDIs. The average reading grade level for First Databank leaflets was 10.6 (SD=2.87), while the reading level for the CMI from Wolters Kluwer was 5.0. The font size varied from 8 to 12-point font. Conclusions: CMI has limited to no warnings about serious and well-known DDIs. Medication information vendors and community pharmacies should work together to improve CMI to help prevent dangerous DDIs.